Please read the Accreditation Information section of the training page to learn about the requirements for receiving credit or a certificate of completion.
Virtual meeting
Via Zoom
Description
As part of the twice-monthly SUD Care Continuum ECHO® series, Joji Suzuki, MD, will describe the GLP-1 drug class and discuss the emerging evidence base for its role in addiction treatment. The didactic will be followed by a de-identified patient case presentation from an ECHO® participant and recommendations from the panel of experts and attendees.
Boston Medical Center's (BMC) drop-in series Substance Use Disorder Care Continuum ECHO® (SUD Care Continuum ECHO®) offers training and support in addiction treatment, with a focus on supporting front line addiction treatment workforce. This includes health providers in Acute Treatment Services (ATS), Crisis Stabilization Services (CSS), Transitional Support Services (TSS), Opioid Treatment Programs (OTP), long-term residential program, sober and recovery homes, primary care, and psychiatry. This free, case-based tele-mentoring program is designed to increase the capacity of health care providers to implement high-quality and evidence-based addiction treatment.
Intended audience
Providers, nurses, social workers, psychologists, peer supports, other clinical staff, and non-clinicians.
Speakers
Joji Suzuki, MD
Dr. Suzuki is the Director of the Division of Addiction Psychiatry and Director of Addictions Education in the Department of Psychiatry, Brigham and Women’s Hospital, and an Assistant Professor of Psychiatry at Harvard Medical School. His areas of clinical and research interests are the assessment and management of substance use disorders and related conditions in general medical settings, motivational interviewing, office-based opioid treatment, implementation of collaborative models of care, and medical education. He is the site director for the Partners Addiction Psychiatry Fellowship, and is involved with teaching medical students, residents, and allied health professionals. He has authored over 30 peer-reviewed manuscripts and book chapters related to addiction psychiatry.
Objectives
Following this training, participants will have the knowledge to:
- Describe the GLP-1 drug class.
- Discuss the emerging evidence base for the role of GLP-1s in addiction treatment.
Sponsored by
Massachusetts Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS).
Funding for out of state attendees is provided by the Opioid Response Network (ORN).
Funding for this initiative was made possible (in part) by grant no. 1H79TI085588-02 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
